The agency has revised its good pharmacovigilance practices guide on risk management systems.
The European Medicines Agency (EMA) has revised module V of the good pharmacovigilance practices (GVP) on risk management systems based on insights from EMA’s Pharmacovigilance Risk Assessment Committee (PRAC). Public consultation on the revised guidelines is open until May 31, 2016.
The revision clarifies the requirements a risk management plan should focus on “to ensure that a risk-proportionate planning of activities directs resources to areas where the need for additional information and risk minimization is greatest. EMA states that the GVP module V should be read in conjunction with GVP module XVI, which focuses on tools for risk minimization.
EMA is also looking to amend the risk management plan template used by drug developers in order to focus the risk management system and simplify transfer of information to regulators. Public consultation on the revised template is also open until May 31, 2016.
Source: EMA
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.